Purpose: Oncogenic conversion of BRAF occurs in∼ 44% of papillary thyroid carcinomas
and 24% of anaplastic thyroid carcinomas. In papillary thyroid carcinomas, this mutation is …

BRAF, a cytoplasmic serine–threonine protein kinase, plays a critical role in cell signaling as
an activator within the mitogen-activated protein kinase (MAPK) pathway. The most common …

Activating mutations in the gene encoding BRAF are the most commonly identified
oncogenic abnormalities in papillary thyroid cancer. In vitro and in vivo models have …

B-Raf is an important mediator of cell proliferation and survival signals transduced via the
Ras-Raf-MEK-ERK cascade. BRAF mutations have been detected in several tumors …

Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon
which novel approaches to the management of thyroid cancer can be developed. A recent …

Activating mutations of the BRAF gene are the most common genetic alterations in papillary
thyroid carcinomas (PTCs) and the T1799A transversion, resulting in BRAF V600E …

BRAF (7q24) encodes a serine/threonine protein kinase, and its expression level varies in
different tissues. Although a high prevalence of BRAF mutation has been suggested as an …

BRAF is a serine/threonine kinase that receives a mitogenic signal from RAS and transmits it
to the MAP kinase pathway. Recent studies have reported that mutations of the BRAF gene …

The B-type Raf kinase (BRAF) protein is a serine/threonine kinase that has an important role
in cellular proliferation, differentiation, and programmed cell death. The BRAF gene has …

Activating mutations in the BRAF kinase gene have recently been reported in human
cancers. The aim of the present study was to determine the frequency of BRAF mutations in …